Improving Screening and Therapy for Hispanic/Latinx at Risk for CKD

CompletedOBSERVATIONAL
Enrollment

59

Participants

Timeline

Start Date

May 18, 2023

Primary Completion Date

April 4, 2025

Study Completion Date

April 4, 2025

Conditions
Type 2 DiabetesChronic Kidney Diseases
Interventions
DIAGNOSTIC_TEST

BP

Blood pressure measurements and HbA1c tests will be conducted to identify participants with or at risk for high blood pressure and/or Type 2 Diabetes. Those identified will be referred to PCP for follow up/treatment.

DIAGNOSTIC_TEST

HbA1c

HbA1c will screen to identify patients with Type 2 diabetes

BEHAVIORAL

PCP Guidelines for Screening and Monitoring Hispanic/Latinx patients for CKD

Guidelines will be developed and provided to PCPs to use with their Hispanic/Latinx patients with or at risk for CKD.

Trial Locations (1)

27708

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Institute on Minority Health and Health Disparities (NIMHD)

NIH

lead

Duke University

OTHER

NCT05734989 - Improving Screening and Therapy for Hispanic/Latinx at Risk for CKD | Biotech Hunter | Biotech Hunter